Drug Database
SK

SKATIII (SK Antithrombin III / SKATIII)

✓ Approved

SK Plasma · SERPINC1 · Cell-based Therapies

What is SKATIII?

SKATIII is a cell-based therapies developed by SK Plasma. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesSK Antithrombin III, SKATIII
CompanySK Plasma
Drug ClassCell-based Therapies
Molecular TargetSERPINC1
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, SK Plasma

Mechanism of Action

Molecular Targets

SKATIII acts on 1 molecular target:

SERPINC1serpin family C member 1 (ATIII, AT3D)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

SKATIII is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved
Vascular disordersThrombosis✓ Approved

Ask about SKATIII